Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53

Hans J. Stricker, Jonathan K. Jay, Michael D. Linden, Pheroze Tamboli, Mahul Amin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives. Mutations of the p53 tumor suppressor gene can result in unregulated cellular growth and have been implicated in numerous malignancies. The objective of this study was to determine whether the detection of mutant p53 by immunohistochemical staining is predictive of progression in clinically localized adenocarcinoma of the prostate. Methods. Immunohistochemical staining for mutant p53 was performed on 40 formalin- fixed radical prostatectomy specimens. Benign glands in the sections served as controls. Immunoreactivity (IR) was categorized semi-quantitatively from 0 to 4 + (0 = no IR, 1 + = 1% to 10%, 2 + = 11% to 40%, 3 + = 41% to 70%, 4 + = 71% to 100%). Results were then compared to Gleason score, Stage (T2 versus T3), surgical margins, lymph node and seminal vesicle involvement, age, race, preoperative prostate-specific antigen (PSA), and biochemical progression. Biochemical progression was defined as a persistently elevated postoperative PSA of 0.2 ng/mL or greater. Results. Thirty-two of the 40 tumors (80%) stained for mutant p53. None of the tumors that did not stain progressed, whereas 20 of 32 (62.5%) of the tumors that did stain progressed, with an overall mean follow-up of 50.8 months. Immunoreactivity did not correlate with any of the known prognostic variables but did have statistically significant correlation with progression by all three statistical methods used (Fisher's exact test, logistic regression, and log-rank test). Conclusions. Strict quality control and newer antigen retrieval techniques reveal p53 abnormalities in many prostate cancers. Immunohistochemical detection of mutant p53 appears to be an independent predictor of progression. These data suggest potential utility of p53 as a preoperative prognostic indicator in localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)366-369
Number of pages4
JournalUrology
Volume47
Issue number3
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasms
Coloring Agents
Staining and Labeling
Neoplasm Grading
Seminal Vesicles
Prostatectomy
Tumor Suppressor Genes
Quality Control
Formaldehyde
Prostate
Adenocarcinoma
Logistic Models
Lymph Nodes
Antigens
Mutation
Growth

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. / Stricker, Hans J.; Jay, Jonathan K.; Linden, Michael D.; Tamboli, Pheroze; Amin, Mahul.

In: Urology, Vol. 47, No. 3, 01.01.1996, p. 366-369.

Research output: Contribution to journalArticle

Stricker, Hans J. ; Jay, Jonathan K. ; Linden, Michael D. ; Tamboli, Pheroze ; Amin, Mahul. / Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. In: Urology. 1996 ; Vol. 47, No. 3. pp. 366-369.
@article{d47abedb19d2436b9fe11d6fdd644300,
title = "Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53",
abstract = "Objectives. Mutations of the p53 tumor suppressor gene can result in unregulated cellular growth and have been implicated in numerous malignancies. The objective of this study was to determine whether the detection of mutant p53 by immunohistochemical staining is predictive of progression in clinically localized adenocarcinoma of the prostate. Methods. Immunohistochemical staining for mutant p53 was performed on 40 formalin- fixed radical prostatectomy specimens. Benign glands in the sections served as controls. Immunoreactivity (IR) was categorized semi-quantitatively from 0 to 4 + (0 = no IR, 1 + = 1{\%} to 10{\%}, 2 + = 11{\%} to 40{\%}, 3 + = 41{\%} to 70{\%}, 4 + = 71{\%} to 100{\%}). Results were then compared to Gleason score, Stage (T2 versus T3), surgical margins, lymph node and seminal vesicle involvement, age, race, preoperative prostate-specific antigen (PSA), and biochemical progression. Biochemical progression was defined as a persistently elevated postoperative PSA of 0.2 ng/mL or greater. Results. Thirty-two of the 40 tumors (80{\%}) stained for mutant p53. None of the tumors that did not stain progressed, whereas 20 of 32 (62.5{\%}) of the tumors that did stain progressed, with an overall mean follow-up of 50.8 months. Immunoreactivity did not correlate with any of the known prognostic variables but did have statistically significant correlation with progression by all three statistical methods used (Fisher's exact test, logistic regression, and log-rank test). Conclusions. Strict quality control and newer antigen retrieval techniques reveal p53 abnormalities in many prostate cancers. Immunohistochemical detection of mutant p53 appears to be an independent predictor of progression. These data suggest potential utility of p53 as a preoperative prognostic indicator in localized prostate cancer.",
author = "Stricker, {Hans J.} and Jay, {Jonathan K.} and Linden, {Michael D.} and Pheroze Tamboli and Mahul Amin",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0090-4295(99)80454-3",
language = "English (US)",
volume = "47",
pages = "366--369",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53

AU - Stricker, Hans J.

AU - Jay, Jonathan K.

AU - Linden, Michael D.

AU - Tamboli, Pheroze

AU - Amin, Mahul

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objectives. Mutations of the p53 tumor suppressor gene can result in unregulated cellular growth and have been implicated in numerous malignancies. The objective of this study was to determine whether the detection of mutant p53 by immunohistochemical staining is predictive of progression in clinically localized adenocarcinoma of the prostate. Methods. Immunohistochemical staining for mutant p53 was performed on 40 formalin- fixed radical prostatectomy specimens. Benign glands in the sections served as controls. Immunoreactivity (IR) was categorized semi-quantitatively from 0 to 4 + (0 = no IR, 1 + = 1% to 10%, 2 + = 11% to 40%, 3 + = 41% to 70%, 4 + = 71% to 100%). Results were then compared to Gleason score, Stage (T2 versus T3), surgical margins, lymph node and seminal vesicle involvement, age, race, preoperative prostate-specific antigen (PSA), and biochemical progression. Biochemical progression was defined as a persistently elevated postoperative PSA of 0.2 ng/mL or greater. Results. Thirty-two of the 40 tumors (80%) stained for mutant p53. None of the tumors that did not stain progressed, whereas 20 of 32 (62.5%) of the tumors that did stain progressed, with an overall mean follow-up of 50.8 months. Immunoreactivity did not correlate with any of the known prognostic variables but did have statistically significant correlation with progression by all three statistical methods used (Fisher's exact test, logistic regression, and log-rank test). Conclusions. Strict quality control and newer antigen retrieval techniques reveal p53 abnormalities in many prostate cancers. Immunohistochemical detection of mutant p53 appears to be an independent predictor of progression. These data suggest potential utility of p53 as a preoperative prognostic indicator in localized prostate cancer.

AB - Objectives. Mutations of the p53 tumor suppressor gene can result in unregulated cellular growth and have been implicated in numerous malignancies. The objective of this study was to determine whether the detection of mutant p53 by immunohistochemical staining is predictive of progression in clinically localized adenocarcinoma of the prostate. Methods. Immunohistochemical staining for mutant p53 was performed on 40 formalin- fixed radical prostatectomy specimens. Benign glands in the sections served as controls. Immunoreactivity (IR) was categorized semi-quantitatively from 0 to 4 + (0 = no IR, 1 + = 1% to 10%, 2 + = 11% to 40%, 3 + = 41% to 70%, 4 + = 71% to 100%). Results were then compared to Gleason score, Stage (T2 versus T3), surgical margins, lymph node and seminal vesicle involvement, age, race, preoperative prostate-specific antigen (PSA), and biochemical progression. Biochemical progression was defined as a persistently elevated postoperative PSA of 0.2 ng/mL or greater. Results. Thirty-two of the 40 tumors (80%) stained for mutant p53. None of the tumors that did not stain progressed, whereas 20 of 32 (62.5%) of the tumors that did stain progressed, with an overall mean follow-up of 50.8 months. Immunoreactivity did not correlate with any of the known prognostic variables but did have statistically significant correlation with progression by all three statistical methods used (Fisher's exact test, logistic regression, and log-rank test). Conclusions. Strict quality control and newer antigen retrieval techniques reveal p53 abnormalities in many prostate cancers. Immunohistochemical detection of mutant p53 appears to be an independent predictor of progression. These data suggest potential utility of p53 as a preoperative prognostic indicator in localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029922216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029922216&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)80454-3

DO - 10.1016/S0090-4295(99)80454-3

M3 - Article

C2 - 8633403

AN - SCOPUS:0029922216

VL - 47

SP - 366

EP - 369

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -